HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
C9145 | Aprepitant | Aponvie | 1mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | No | 2023 | Mar 17, 2023 | In Use | ||
C9146 | Mirvetuximab soravtansine | Elahere | 1mg | Immunotherapy | Drug Antibody Conjugate | FR-alpha, DM4 | No | 2022 | Mar 17, 2023 | Jul 11, 2023 | No Longer Used | |
J9323 | Pemetrexed ditromethamine | Pemetrexed ditromethamine | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Jul 11, 2023 | In Use | ||
J9347 | Tremelimumab-actl | Imjudo | 1mg | Immunotherapy | Monoclonal Antibody | CTLA-4 | No | 2022 | Jul 11, 2023 | In Use | ||
J9380 | Teclistamab cqyv | Tecvayli | 0.5mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2022 | Jul 11, 2023 | In Use | ||
J9056 | Bendamustine | Vivimusta | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2022 | Jul 11, 2023 | In Use | ||
J9259 | Paclitaxel (American Regent) | Paclitaxel (American Regent) | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2023 | Jul 11, 2023 | In Use | ||
J9063 | Mirvetuximab soravtansine | Elahere | 1mg | Immunotherapy | Drug Antibody Conjugate | FR-alpha, DM4 | No | 2022 | Jul 11, 2023 | In Use | ||
J9059 | Bendamustine (Baxter) | Bendamustine (Baxter) | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2022 | Jul 11, 2023 | In Use | ||
J9058 | Bendamustine (Apotex) | Bendamustine (Apotex) | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2023 | Jul 11, 2023 | In Use | ||
J9322 | Pemetrexed (Bluepoint) | Pemetrexed (Bluepoint) | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2022 | Jul 11, 2023 | In Use | ||
J9350 | Mosunetuzumab-axgb | Lunsumio | 1mg | Immunotherapy | Monoclonal Antibody | CD20, CD3 | No | 2022 | Jul 11, 2023 | In Use | ||
J9345 | Retifanlimab-dlwr | Zynyz | 1mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2023 | Aug 28, 2023 | In Use | ||
J9064 | Cabazitaxel (Sandoz) | Cabazitaxel | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2023 | Aug 28, 2023 | In Use | ||
C9155 | Epcoritamab-bysp | Epkinly | 0.16mg | Immunotherapy | Monoclonal Antibody | CD20, CD3 | No | 2023 | Aug 28, 2023 | Dec 7, 2023 | No Longer Used | |
J9051 | Bortezomib (Maia) | Bortezomib | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | Yes | 2022 | Aug 28, 2023 | In Use | ||
J9321 | Epcoritamab-bysp | Epkinly | 0.16mg | Immunotherapy | Monoclonal Antibody | CD20, CD3 | No | 2023 | Dec 7, 2023 | In Use | ||
J9255 | Methotrexate (Accord) | Methotrexate | 50mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2014 | Dec 7, 2023 | In Use | ||
J9286 | Glofitamab-gxbm | Columvi | 2.5mg | Immunotherapy | Monoclonal Antibody | CD20, CD3 | No | 2023 | Dec 7, 2023 | In Use | ||
C9163 | Talquetamab | Talvey | 0.25mg | Immunotherapy | T Cell Receptor (TCR) | GPRC5D, CD3 | No | 2023 | Dec 7, 2023 | Apr 17, 2024 | No Longer Used | |
J9324 | Pemetrexed disodium | Pemrydi-rtu | 10mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2023 | Dec 7, 2023 | In Use | ||
C9165 | Elranatamab-bcmm | Elrexfio | 1mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2023 | Dec 7, 2023 | Apr 17, 2024 | No Longer Used | |
J9072 | Cyclophosphamide (Dr Reddy's) | Cyclophosphamide | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2023 | Dec 7, 2023 | In Use | ||
J9052 | Carmustine (Accord) | Carmustine | 100mg | Chemotherapy | Alkylating Agent | Nitrosurea | No | 2022 | Dec 7, 2023 | In Use | ||
J9172 | Docetaxel (Ingenus) | Docetaxel | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2017 | Dec 7, 2023 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.